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etters to the Editor
cute  kidney  injury  secondary  to  rhabdomyolysis  in a
onagenarian patient  taking  statins.  Lessons  to  be
onsideredracaso  renal  agudo  secundario  a  rabdomiólisis  por  estatinas  en  una
 te
The special feature of this report lies in the fact that our patientaciente  nonagenaria.  Lecciones  a
ear Editor,
lderly patients with chronic kidney disease (CKD) are more
rone to develop episodes of acute kidney injury (AKI),
requently resulting from drug dosage non adjusted for
lomerular ﬁltration rate (GFR) or by drug-to-drug interactions
ue to CKD. We  present a case of AKI secondary to rhab-
omyolysis in a nonagenarian patient taking statins as well as
ther potentially nephrotoxic drugs. A comment on practical
essons to be learned has also been included.
A 91-year-old patient with a history of hypertension (HTN)
nd hypercholesterolaemia diagnosed at the age of 85 on treat-
ent with atorvastatin 10 mg.  Two years later the patient
as switched to rosuvastatin 20 mg  because of poor control
f cholesterol levels. Treatment with this drug was contin-
ed with normalization of cholesterol levels. The rest of
reatment included telmisartan 80 mg,  hydrochlorothiazide
5 mg,  esomeprazole 40 mg and ibuprofen 600 mg/24 h for the
anagement of arthralgia. The serum creatinine levels was
.55 mg/dl.
The patient presented at the emergency room with a his-
ory of 72 h of sudden right ﬂank pain without irradiation,
ccompanied by oliguria, and no fever. She also complained
f muscle weakness in lower extremities.
Physical examination showed no remarkable ﬁndings
xcept for decreased osteotendinous reﬂexes in lower extrem-
ties.Lab results upon admission were: haemoglobin 13.3 g/dl,
lucose 99 mg/dl, creatinine 4.47 mg/dl, urea 1.24 g/l, albumin
.28 g/dl, AST 360 U/l, ALT 165 U/l, GGT 11 U/l, alkaline
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abdomiólisis por estatinas en una paciente nonagenaria. Lecciones a tner  en  cuenta
phosphatase 93 U/l, amylase 58 U/l, total cholesterol
117 mg/dl, uric acid 6.3 mg/dl, sodium 138 mEq/l, potas-
sium 2.93 mEq/l, chloride 90.7 mEq/l, pH 7.45, pCO2 38 mmHg,
CO3H 26.1 mmol/l; proteinuria: 0.6 g/24 h, and CPK 9.612 /l.
Abdominal ultrasound showed kidneys normal in size and
structure, without evidence of pelvicalyceal ectasia.
Fluid therapy was initiated, followed by progressive recov-
ery of renal function together with complete normalization of
CPK and transaminases levels. Creatinine was 1.9 mg/dl at dis-
charge and 1.44 mg/dl 2 months later according to outpatient
readings.
Our patient had an episode of rhabdomyolysis-related AKI,
which was likely associated to the use of rosuvastatin since
no other cause of rabdomyilysis was detected.1
Of note, the patient, who had CKD stage 4 according to
KDIGO2 with a baseline CKD-EPI GFR of 29.06 ml/min/1.73 m2.
was receiving excessive dose of rosuvastatin.
The present case illustrate the importance of outpatient
measurements of GFR in elderly patients.3 According to its
core data sheet, the use of rosuvastatin is not recommended
in patients with a GFR <30 ml/min, with a starting dose of
5 mg/day indicated for elderly patients. The stage of CKD may
have been missed in primary care if the GFR was not measured
using equations.
The undeniable usefulness of statins for primary preven-
tion among patients aged 85 and over can also be discussed.4o-Gonzalo O, Alvarez-Lipe R. Fracaso renal agudo secundario a
ener en cuenta. Nefrologia. 2016;36:181–182.
developed rhabdomyolysis following long-term treatment
with statins (5 years) an almost unparalleled case in the
literature, suggesting that the complication may arise at any
r182  n e f r o l o g i a. 2 0 1 6;3 6(2):181–191
time. Muscle necrosis has been described following treatment
with both drugs.5,6 Between 15 and 33% of patients develop
AKI.7 Up to 37% of them require haemodialysis. Mortality is
5%, although it rises to 25% when complicated by AKI.
The mechanism of muscle toxicity is not fully understood.
Statins may interfere in the synthesis of the Q10 coenzyme
(CoQ10 or ubiquinone) involved in energy production of mus-
cle cells.8
Muscular symptoms usually start weeks or months after
the initiation of treatment, but just as in our patient, it may
occur at any time. In a series including 44 patients, mean
treatment duration before symptoms was 6.3 months (range:
0.25–48). Symptoms resolved following drug withdrawal after
a mean of 2.3 months (range: 0.25–14).9
Also important is the fact that the patient was taking the
following drugs: a non-steroid anti-inﬂammatory drug, an
angiotensin receptor antagonist, and a diuretic. This combi-
nation is sometimes referred to as a “Triple whammy” and
has been associated with a higher incidence of AKI.10 In our
patient, other drugs may have led to decreased GFR and the
development of muscle necrosis.
In summary, our case highlights the need for a thorough
assessment of the risk-beneﬁt proﬁle when prescribing drugs
to elderly patients with CKD, which should be staged based on
the measurement of GFR. Statin-associated rhabdomyolysis
may occur at any time of the disease course, while concomi-
tant use with certain drugs may increase toxicity.
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Acute  renal  colic:  Beyond  kidney  stones
Cólico  renal  agudo:  más  allá  de  los  cálculos  renales
Dear Editor,
A 59-year-old woman  without relevant past medical history
presented with hematuria and renal colic. After a negative
Renal abnormalities are frequently described in patients
with sickle hemoglobinopathies, but SCT patients (heterozy-
gous carriers, with one sickle cell gene and one normal gene)
are mostly asymptomatic.1 However sickle cell crisis can occur
if the patient is exposed to hypoxic conditions, high alti-diagnostic work-up, sickling vaso-occlusive crisis in the set-
ting of sickle cell trait (SCT) was diagnosed. This report aims to
raise awareness that SCT should be included in the differential
diagnosis of unexplained hematuria and/or renal colic.tude and intense physical exercise.1 Acute events include
vaso-occlusive crises such as papillary necrosis of the kidney,
ischemic stroke and infections.2
